MedPath

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Phase 3
Terminated
Conditions
Benign Prostatic Hypertrophy
Interventions
Registration Number
NCT00449150
Lead Sponsor
AEterna Zentaris
Brief Summary

Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and among those aged 50 to 80, about 40% report moderate or severe urinary symptoms of prostatism. The aim of treatment is to improve patients' quality of life which primarily depends on the severity of the symptoms of BPH. Current treatments of BPH have a benefit / risk ratio which leaves room for improvement.

For this study, study medication (Cetrorelix pamoate or placebo) is administered by injection in the buttocks (Intramuscular). All patients completing the double-blind portion (Week 0 to 52) are eligible to receive the active drug during the open-label part of the study (Week 52 to 90).

Detailed Description

The objectives of the study are to develop a safe and tolerable intermittent dosage regimen of cetrorelix pamoate that provides prolonged improvement in BPH-related signs and symptoms.

Patients will enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS).

Patients will then be allocated to study drug in a double-blind, randomized, double-dummy, placebo-controlled fashion.

Patients will be administered an IM injection of study drug at Week 0, 2, 26 and 28 and will be followed up to Week 52.

Then, in an open label fashion, patients will be administered an IM injection of study drug at Week 52, 54, 78 and 80 and will be followed up to Week 90.

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
667
Inclusion Criteria
  • Benign Prostatic Hyperplasia, based on medical history
  • Voiding symptoms
Exclusion Criteria
  • Urgent need for prostate surgery or prior surgical treatment of the prostate or bladder
  • Major organ dysfunction
  • Eczema (atopic dermatitis) treated during the last 6 months
  • Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior randomization or with α blockers or saw palmetto within the last 6 weeks prior to randomization
  • Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy
  • History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment Group B: CET 78 mg + 52 mgPlaceboTreatment course 1: Cetrorelix 78 mg + 52 mg * Week 0: 52 mg CET (2 injections) * Week 2: 26 mg CET (1 injection) Treatment course 2: * Week 26: 52 mg CET (2 injections) * Week 28: Placebo (1 injection) 4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
Treatment Group C: PlaceboPlaceboTreatment course 1: * Week 0: placebo (2 injections) * Week 2: placebo (1 injection) Treatment course 2: * Week 26: placebo (2 injections) * Week 28: placebo (1 injection) 4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
Treatment Group A: CET 78 mg + 78 mgCetrorelix 78 mg + 78 mgTreatment course 1: Cetrorelix 78 mg + 78 mg * Week 0: 52 mg CET (2 injections) * Week 2: 26 mg CET (1 injection) Treatment course 2: * Week 26: 52 mg CET (2 injections) * Week 28: 26 mg CET(1 injection) 4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
Treatment Group B: CET 78 mg + 52 mgCetrorelix 78 mg + 52 mgTreatment course 1: Cetrorelix 78 mg + 52 mg * Week 0: 52 mg CET (2 injections) * Week 2: 26 mg CET (1 injection) Treatment course 2: * Week 26: 52 mg CET (2 injections) * Week 28: Placebo (1 injection) 4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient.
Primary Outcome Measures
NameTimeMethod
International Prostate Symptoms Score (IPSS)Baseline and 52 weeks

The International Prostate Symptoms Score (IPSS) score of benign prostata hyperplasia (BPH) symptoms is calculated based on a patient questionnaire assessing 7 items (incomplete voiding, frequency, intermittency, urgency, weak stream, hesitancy, nocturia) on a scale from 0 (best) to 5 (worst); total range: 0 points (best) to 35 points (worst)

Secondary Outcome Measures
NameTimeMethod
Time Course of Quality of LifeQuality of life assessment in the following weeks: 4,12,26,30,38,46,52

The time course of quality of life: assessed by the following disease specific quality of life:"If you were to spend the rest of your life with the urinary conditions just the way it is now, how would you feel about that?" The rating scale is comprising a range of values from 0 to 6, with = delighted, 1 = pleased, 2 = mostly satisfied, 3 = mixed, 4 = mostly dissatisfied, 5 = unhappy, 6 = terrible.

Trial Locations

Locations (68)

Medical Affiliated Research Center, Inc.

🇺🇸

Huntsville, Alabama, United States

Urology Group of Westrn Arkansas

🇺🇸

Fort Smith, Arkansas, United States

South Orange County Medical Research Center

🇺🇸

Laguna Hills, California, United States

California Professionnal Research

🇺🇸

Newport Beach, California, United States

William G. Moseley

🇺🇸

San Diego, California, United States

West Coast Clinical Research

🇺🇸

Tarzana, California, United States

Western Clinical Research, Inc.

🇺🇸

Torrance, California, United States

Urology Research Options

🇺🇸

Aurora, Colorado, United States

Urologic Oncology

🇺🇸

Aurora, Colorado, United States

Genitourinary Surgical Consultants

🇺🇸

Denver, Colorado, United States

Scroll for more (58 remaining)
Medical Affiliated Research Center, Inc.
🇺🇸Huntsville, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.